How can the same mTORC1 activity produce different outputs — and which of them carries ageing?

Framing gap · evidence stands at: Lifespan in mice · Atlas ID F2

The gap

The same amount of mTORC1 activity does not have to give the same result. Each of the enzyme's targets has its own sensitivity: some stay switched on when mTORC1 is only partly blocked, others switch off first (Kang 2013). One target, TFEB, is reached by a separate route the others do not need (Napolitano 2020). Most of the argument about ageing is about how hard to press the brake. Hardly anyone asks which of these outputs actually needs slowing, and in muscle, fixing one downstream branch rescues the problem while removing another does nothing.

Technical framing: The field asks how much mTORC1 to inhibit, and lately which complex to spare. It rarely asks how one activity state is turned into several different outputs, or which of them needs inhibiting at all. Yet the outputs behave differently. Phosphorylation sites differ in intrinsic substrate quality, so partial inhibition by rapamycin or starvation removes poor substrates first and leaves good ones phosphorylated (KAN2013). TFEB is reached by a RagC/D-dependent route that S6K1 and 4E-BP1 do not need (NAP2020). In muscle, the 4E-BP1 arm and the S6K1 arm separate: activating 4E-BP1 rescues a sarcopenia model and deleting S6K1 does not. Bi-steric inhibitors reactivate 4E-BP1 where rapalogs cannot. Amplitude, duration and location are each candidate ways a cell could select among outputs; ageing is one place where the choice would matter.

What changed

Substrate selectivity has moved from a curiosity to a stated paradigm shift in the 2026 review literature, on the back of results showing that where mTORC1 sits and which substrates it reaches are not the same variable as how active it is. On the therapeutic side, bi-steric inhibitors are designed to change the output profile rather than only the output amount, adding suppression of 4E-BP1 phosphorylation to mTORC1 selectivity (Mahauad-Fernandez, Cell Chem Biol 2025, PMID 40803322), and they have now been through a human phase 1 (Schram, Clin Cancer Res 2025, PMID 41056387).

What is still open

Which outputs are required for geroprotection. No lifespan experiment has compared mTORC1 outputs at matched mTORC1 activity. Single-output genetics exists - S6K1 deletion extends female mouse lifespan (SEL2009) and 4E-BP mediates dietary-restriction lifespan extension in flies (ZID2009) - but there is no 4E-BP1-arm-only ITP cohort, no S6K1-arm-only cohort at matched mTORC1 activity, and no bi-steric lifespan data in any species.

How it could be tested

An ITP-style lifespan protocol comparing rapamycin against a bi-steric at doses matched for total mTORC1 inhibition but differing in 4E-BP1 engagement. If lifespan tracks 4E-BP1 dephosphorylation rather than overall mTORC1 suppression, the target is an output, not the complex. Genetic arm: 4E-BP1 and S6K1 manipulations on a common background with the same endpoints.

Why it matters

It would change what a geroprotective drug is supposed to do. Sparing mTORC2 is a question about avoiding harm; choosing outputs is a question about where the benefit lives, and it may explain why deeper inhibition is not reliably better.

Evidence behind this question

Gap not yet confirmed by a logged literature search. The text states that the comparison was not found, but the literature search behind that statement is not logged. (checked 2026-10-15)

How it relates to the other frontier questions: Amplitude, duration (F1) and location (F3) are each a candidate way for a cell to select among outputs.

Direct evidence for a premise

• Kang et al. 2013 (KAN2013) — Phosphorylation sites differ in how sensitive they are to mTORC1 inhibition and starvation, so partial inhibition removes poor substrates first.
• Napolitano et al. 2020 (NAP2020) — TFEB is phosphorylated by a RagC/D-dependent route that S6K1 and 4E-BP1 do not need.

Related evidence

• Selman et al. 2009 (SEL2009) — S6K1 deletion extends lifespan in female mice, a single-output manipulation.
• Zid et al. 2009 (ZID2009) — 4E-BP mediates lifespan extension under dietary restriction in flies.
• Mahauad-Fernandez et al. 2025 (PMID 40803322, not in the Atlas corpus) — Bi-steric inhibitors are designed to add suppression of 4E-BP1 phosphorylation to mTORC1 selectivity.
• Schram et al. 2025 (SCH2025) — Phase 1 human trial of a bi-steric mTORC1 inhibitor in advanced solid tumours. It says nothing about lifespan.

Assumption not yet verified

• 4E-BP1 and S6K1 arms in muscle — The text says activating 4E-BP1 rescues a sarcopenia model while deleting S6K1 does not. No citation is given yet.

The grouping is the curator's reading of how each paper is used here. It has not been checked by a second reader.

Bears on these open questions

• Does mTORC1-selective dosing extend lifespan, and is rapamycin's glucose intolerance a cost at all?
• Muscle-sparing, pulsed mTORC1 inhibition
• Is autophagy actually REQUIRED for the mammalian lifespan benefit?

← All frontier questions · Open questions